序号 |
标题 |
次数 |
作者 |
发布时间 |
73126 |
cas:1061569-06-9,4-formyl-N-(2-(2-hydroxyethoxy)ethyl)benzamide ADC抗体偶联药物 |
75 |
zyl |
2024-12-19 |
73127 |
DBCO-PEG4-VA-PBD,2241644-09-5,ADC定制 |
72 |
wyh |
2024-12-19 |
73128 |
Val-Cit-PAB-MMAE,cas:644981-35-1,ADC定制 |
76 |
wyh |
2024-12-19 |
73129 |
DOTA-GMSH 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)偶联α-黑素细胞刺激素(α-MSH)类似物 |
101 |
h |
2024-12-19 |
73130 |
mDPR-Val-Cit-PAB-MMAE,1491152-26-1,ADC定制 |
75 |
wyh |
2024-12-19 |
73131 |
G3-(Gd-DTPA)(24)DOTA-钆(Gd)大分子造影剂 |
166 |
h |
2024-12-19 |
73132 |
DOTA-多柔比星 DOTA-DOX |
104 |
h |
2024-12-19 |
73133 |
聚(HPMA)-c(RGDyK)-DOTA |
57 |
h |
2024-12-19 |
73134 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)螯合剂共轭的应变环辛烯衍生物二苄基环辛烯(DBCO) |
78 |
h |
2024-12-19 |
73135 |
PDDEC-NB;2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate |
72 |
zyl |
2024-12-19 |
73136 |
(67)Ga-DOTA复合物共轭二膦酸盐(67)Ga-DOTA-Bn-SCN-HBP |
106 |
h |
2024-12-19 |
73137 |
MWCNT/PEI-FI-DOTA(Gd)-PEG 异硫氰酸荧光素(FI)和钆(Gd)螯合剂共价接枝聚乙烯亚胺修饰的多壁碳纳米管 |
117 |
h |
2024-12-19 |
73138 |
DOTA-Cys-hAb47 螯合剂DOTA偶联半胱氨酸-抗EphB4抗体hAb47和hAb131 |
152 |
h |
2024-12-19 |
73139 |
1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-F(ab)2-曲妥珠单抗 |
78 |
h |
2024-12-19 |
73140 |
DOTA-MG11(DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp)DOTA肽缀合物 |
100 |
h |
2024-12-19 |
73141 |
AcLys-PABC-VC-Aur0101, cas:1438851-17-2,ADC定制 |
122 |
wyh |
2024-12-19 |
73142 |
cas:107348-47-0,2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate ADC抗体偶联药物 |
68 |
zyl |
2024-12-19 |
73143 |
SMCC-DM4 , cas:1228105-52-9,ADC定制 |
65 |
wyh |
2024-12-19 |
73144 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
73 |
zyl |
2024-12-19 |
73145 |
MA-PEG8-VA-PAB-SG3199,ADC定制 |
87 |
wyh |
2024-12-19 |
73146 |
Acid-PEG4-Val-Cit-PAB-MMAE |
62 |
zyl |
2024-12-19 |
73147 |
MC-Val-Cit-PAB-Indibulin,cas:2055896-95-0,ADC定制 |
81 |
wyh |
2024-12-19 |
73148 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
78 |
zyl |
2024-12-19 |
73149 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
77 |
zyl |
2024-12-19 |
73150 |
MC-Sq-Cit-PAB-Dolastatin10 ,cas:1941168-65-5,ADC定制 |
93 |
wyh |
2024-12-19 |
73151 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
82 |
zyl |
2024-12-19 |
73152 |
N3-PEG4-DYKDDDD-Doxorubicin,ADC定制 |
99 |
wyh |
2024-12-19 |
73153 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
64 |
zyl |
2024-12-19 |
73154 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
85 |
zyl |
2024-12-19 |
73155 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
81 |
zyl |
2024-12-19 |
73156 |
MC-GGFG-DX8951 cas:1600418-29-8 |
74 |
zyl |
2024-12-19 |
73157 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
88 |
h |
2024-12-19 |
73158 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
182 |
zyl |
2024-12-19 |
73159 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
87 |
h |
2024-12-19 |
73160 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
113 |
h |
2024-12-19 |
73161 |
VC-SECO DUBA analogue,ADC定制 |
91 |
wyh |
2024-12-19 |
73162 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
82 |
h |
2024-12-19 |
73163 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
107 |
h |
2024-12-19 |
73164 |
Vc-MMAD cas:1401963-17-4的结构式 |
71 |
zyl |
2024-12-19 |
73165 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
94 |
h |
2024-12-19 |
73166 |
CL2A-SN38,cas:1279680-68-0,ADC定制 |
157 |
wyh |
2024-12-19 |
73167 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
72 |
h |
2024-12-19 |
73168 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
145 |
h |
2024-12-19 |
73169 |
MC-MMAF , cas:863971-19-1,ADC定制 |
109 |
wyh |
2024-12-19 |
73170 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
131 |
zyl |
2024-12-19 |